# OnCo record paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026" ;
  schema:name "NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer"@en ;
  schema:description "Adding ipilimumab to nivolumab for metastatic anal cancer after chemotherapy did not improve response, progression-free survival or overall survival and doubled severe side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO-25-00929>, <https://pubmed.ncbi.nlm.nih.gov/41499716/> ;
  schema:sameAs <https://doi.org/10.1200/JCO-25-00929> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Morris VK, Ciombor KK, Xiao L, et al." ;
  onco:cancers <https://onco.cc/cancers/metastatic-anal-cancer/>, <https://onco.cc/cancers/anal/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:trials <https://onco.cc/trials/nci9673/> ;
  onco:journals <https://onco.cc/journals/jco/> .